Cetera Investment Advisers Grows Stock Holdings in Exact Sciences Corporation (NASDAQ:EXAS)

Cetera Investment Advisers lifted its holdings in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 6.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 88,233 shares of the medical research company’s stock after purchasing an additional 5,596 shares during the period. Cetera Investment Advisers’ holdings in Exact Sciences were worth $3,820,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC grew its holdings in shares of Exact Sciences by 2,804.8% during the 1st quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 589 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Exact Sciences during the 1st quarter valued at $34,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Exact Sciences during the 4th quarter valued at $45,000. Ostrum Asset Management grew its holdings in shares of Exact Sciences by 28.4% during the 4th quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company’s stock valued at $134,000 after purchasing an additional 527 shares during the last quarter. Finally, Allworth Financial LP grew its holdings in shares of Exact Sciences by 14.3% during the 1st quarter. Allworth Financial LP now owns 2,986 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 373 shares during the last quarter. Institutional investors own 88.82% of the company’s stock.

Insider Transactions at Exact Sciences

In related news, Director Katherine S. Zanotti sold 3,207 shares of Exact Sciences stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $53.20, for a total transaction of $170,612.40. Following the completion of the transaction, the director directly owned 72,759 shares of the company’s stock, valued at $3,870,778.80. This trade represents a 4.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

EXAS has been the topic of several recent research reports. Robert W. Baird increased their target price on shares of Exact Sciences from $69.00 to $72.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. Guggenheim reissued a “buy” rating and issued a $60.00 price target on shares of Exact Sciences in a report on Friday, April 11th. Royal Bank Of Canada raised their price target on shares of Exact Sciences from $52.00 to $54.00 and gave the stock a “sector perform” rating in a report on Friday, May 2nd. Evercore ISI raised their price target on shares of Exact Sciences from $66.00 to $68.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Finally, Mizuho initiated coverage on shares of Exact Sciences in a report on Thursday, April 10th. They issued an “outperform” rating and a $60.00 price target on the stock. Two research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Exact Sciences has an average rating of “Moderate Buy” and an average target price of $70.50.

Exact Sciences Trading Down 1.9%

Shares of NASDAQ EXAS opened at $46.83 on Tuesday. Exact Sciences Corporation has a 1 year low of $39.97 and a 1 year high of $72.83. The stock has a market cap of $8.83 billion, a P/E ratio of -8.50, a price-to-earnings-growth ratio of 10.20 and a beta of 0.93. The firm has a 50-day moving average of $52.55 and a 200 day moving average of $50.26. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.73 and a quick ratio of 2.38.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.